First in Human Study of M1069 in Advanced Solid Tumours

Official Title

First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of M1069 in Participants With Metastatic or Locally Advanced Unresectable Solid Tumours

Summary:

The main purpose of this study is to determine the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and early signs of efficacy of M1069 in participants with advanced solid malignancies.

Trial Description

Primary Outcome:

  • Safety Profile as Assessed by Incidence of Adverse Events (AEs), Treatment-Related AEs and Dose-Limiting Toxicities (DLTs)
Secondary Outcome:
  • Pharmacodynamic Assessment by Phosphorylated cAMP Response Element-binding Protein (pCREB) Level in ex-vivo Stimulated Blood
  • Change from Baseline in Tumour Microenvironment (TME) in Available Paired Tumour Biopsies at Cycle 2 Day 15
  • Pharmacokinetic (PK) Plasma Concentrations of M1069
  • Objective Response (OR) According to Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST v1.1), as Assessed by Investigator
  • Duration of Response (DoR)
  • Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST v1.1), as Assessed by Investigator
  • Change from Baseline in Corrected QT (QTc) Interval Over Time

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society